101 related articles for article (PubMed ID: 29529279)
21. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
[TBL] [Abstract][Full Text] [Related]
22. Proton myo-inositol cotransporter is a novel γ-secretase associated protein that regulates Aβ production without affecting Notch cleavage.
Teranishi Y; Inoue M; Yamamoto NG; Kihara T; Wiehager B; Ishikawa T; Winblad B; Schedin-Weiss S; Frykman S; Tjernberg LO
FEBS J; 2015 Sep; 282(17):3438-51. PubMed ID: 26094765
[TBL] [Abstract][Full Text] [Related]
23. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W
Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676
[TBL] [Abstract][Full Text] [Related]
24. In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat.
Best JD; Jay MT; Otu F; Churcher I; Reilly M; Morentin-Gutierrez P; Pattison C; Harrison T; Shearman MS; Atack JR
J Pharmacol Exp Ther; 2006 May; 317(2):786-90. PubMed ID: 16443723
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N
Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902
[TBL] [Abstract][Full Text] [Related]
26. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.
Barten DM; Meredith JE; Zaczek R; Houston JG; Albright CF
Drugs R D; 2006; 7(2):87-97. PubMed ID: 16542055
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.
Lanz TA; Wood KM; Richter KE; Nolan CE; Becker SL; Pozdnyakov N; Martin BA; Du P; Oborski CE; Wood DE; Brown TM; Finley JE; Sokolowski SA; Hicks CD; Coffman KJ; Geoghegan KF; Brodney MA; Liston D; Tate B
J Pharmacol Exp Ther; 2010 Jul; 334(1):269-77. PubMed ID: 20363853
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid β-Amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses.
Lu Y; Barton HA; Leung L; Zhang L; Hajos-Korcsok E; Nolan CE; Liu J; Becker SL; Wood KM; Robshaw AE; Taylor CK; O'Neill BT; Brodney MA; Riddell D
Neurodegener Dis; 2013; 12(1):36-50. PubMed ID: 22922480
[TBL] [Abstract][Full Text] [Related]
29. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
[TBL] [Abstract][Full Text] [Related]
30. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.
Pant S; Jones SF; Kurkjian CD; Infante JR; Moore KN; Burris HA; McMeekin DS; Benhadji KA; Patel BKR; Frenzel MJ; Kursar JD; Zamek-Gliszczynski MJ; Yuen ESM; Chan EM; Bendell JC
Eur J Cancer; 2016 Mar; 56():1-9. PubMed ID: 26798966
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological properties of a novel and potent γ-secretase modulator as a therapeutic option for the treatment of Alzheimer's disease.
Murakami K; Watanabe T; Koike T; Kamata M; Igari T; Kondo S
Brain Res; 2016 Feb; 1633():73-86. PubMed ID: 26707977
[TBL] [Abstract][Full Text] [Related]
32. Identification of two novel synaptic γ-secretase associated proteins that affect amyloid β-peptide levels without altering Notch processing.
Frykman S; Teranishi Y; Hur JY; Sandebring A; Yamamoto NG; Ancarcrona M; Nishimura T; Winblad B; Bogdanovic N; Schedin-Weiss S; Kihara T; Tjernberg LO
Neurochem Int; 2012 Jul; 61(1):108-18. PubMed ID: 22521230
[TBL] [Abstract][Full Text] [Related]
33. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
Hyde LA; McHugh NA; Chen J; Zhang Q; Manfra D; Nomeir AA; Josien H; Bara T; Clader JW; Zhang L; Parker EM; Higgins GA
J Pharmacol Exp Ther; 2006 Dec; 319(3):1133-43. PubMed ID: 16946102
[TBL] [Abstract][Full Text] [Related]
34. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
Portelius E; Van Broeck B; Andreasson U; Gustavsson MK; Mercken M; Zetterberg H; Borghys H; Blennow K
J Alzheimers Dis; 2010; 21(3):1005-12. PubMed ID: 20634579
[TBL] [Abstract][Full Text] [Related]
35. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels.
Schedin-Weiss S; Inoue M; Hromadkova L; Teranishi Y; Yamamoto NG; Wiehager B; Bogdanovic N; Winblad B; Sandebring-Matton A; Frykman S; Tjernberg LO
Alzheimers Res Ther; 2017 Aug; 9(1):57. PubMed ID: 28764767
[TBL] [Abstract][Full Text] [Related]
36. The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers.
Soares HD; Gasior M; Toyn JH; Wang JS; Hong Q; Berisha F; Furlong MT; Raybon J; Lentz KA; Sweeney F; Zheng N; Akinsanya B; Berman RM; Thompson LA; Olson RE; Morrison J; Drexler DM; Macor JE; Albright CF; Ahlijanian MK; AbuTarif M
J Pharmacol Exp Ther; 2016 Jul; 358(1):138-50. PubMed ID: 27189973
[TBL] [Abstract][Full Text] [Related]
37. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
38. Specific combinations of presenilins and Aph1s affect the substrate specificity and activity of γ-secretase.
Yonemura Y; Futai E; Yagishita S; Kaether C; Ishiura S
Biochem Biophys Res Commun; 2016 Sep; 478(4):1751-7. PubMed ID: 27608597
[TBL] [Abstract][Full Text] [Related]
39. Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool.
van Maanen EM; van Steeg TJ; Michener MS; Savage MJ; Kennedy ME; Kleijn HJ; Stone JA; Danhof M
J Pharmacol Exp Ther; 2016 Apr; 357(1):205-16. PubMed ID: 26826190
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of carbon-14 and stable isotope labeled Avagacestat: a novel gamma secretase inhibitor for the treatment of Alzheimer's disease.
Burrell RC; Easter JA; Cassidy MP; Gillman KW; Olson RE; Bonacorsi SJ
J Labelled Comp Radiopharm; 2014 Aug; 57(10):600-5. PubMed ID: 25196195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
